Mainz Biomed (MYNZ) Debt to Equity (2020 - 2025)
Mainz Biomed's Debt to Equity history spans 5 years, with the latest figure at $0.17 for Q4 2024.
- For Q4 2024, Debt to Equity fell 88.71% year-over-year to $0.17; the TTM value through Dec 2024 reached $0.17, down 88.71%, while the annual FY2024 figure was $0.17, 88.71% down from the prior year.
- Debt to Equity for Q4 2024 was $0.17 at Mainz Biomed, down from $1.5 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.5 in Q4 2023 and bottomed at -$0.01 in Q4 2020.
- The 5-year median for Debt to Equity is $0.0 (2021), against an average of $0.33.
- The largest annual shift saw Debt to Equity surged 65403.63% in 2023 before it crashed 88.71% in 2024.
- A 5-year view of Debt to Equity shows it stood at -$0.01 in 2020, then soared by 139.98% to $0.0 in 2021, then crashed by 36.18% to $0.0 in 2022, then soared by 65403.63% to $1.5 in 2023, then tumbled by 88.71% to $0.17 in 2024.
- Per Business Quant, the three most recent readings for MYNZ's Debt to Equity are $0.17 (Q4 2024), $1.5 (Q4 2023), and $0.0 (Q4 2022).